Juan Fernando Buestán Zambrano, María de Lourdes Rodríguez Coyago
{"title":"Metastasizing Ameloblastoma: A Systematic Review in Search of Clinicopathological Predictors","authors":"Juan Fernando Buestán Zambrano, María de Lourdes Rodríguez Coyago","doi":"10.31487/J.DOBCR.2021.03.01","DOIUrl":null,"url":null,"abstract":"Introduction: Ameloblastoma is a benign odontogenic tumor that is aggressive and localised in nature, \nlisted as the first or second most prevalent odontogenic tumor and rarely tends to metastasis, but when it \ndoes, it receives the definition adopted by the WHO in 2017 of metastasizing ameloblastoma.\nMaterials and Methods: This systematic review of clinical case reports of metastasizing ameloblastoma \nfrom the last 10 years, collected from PubMed, ScienceDirect and Cochrane digital databases, aims to search \nfor association between clinical/pathological and/or molecular parameters of ameloblastoma and its \nmetastatic potential.\nResults: The targeted search yielded 14 publications with a total of 18 clinical cases, which showed a mean \nage for diagnosis of metastasizing ameloblastoma of 46 years, with no gender predilection and a high \nprobability of occurrence in the yellow Asian race, favouring a pattern of distant dissemination. The highest \nfrequency of metastasis was associated with mandibular primary lesions diagnosed in young patients, and \nthe most frequently found variant was the multicystic solid type, follicular subtype; distant metastasis was \nthe predominant form of presentation, with the lungs being the main target.\nConclusion: At the moment, there is nothing that can predict metastatic potential in ameloblastoma. More \nstandardised studies exploring the molecular terrain are needed, as this is a key and understudied factor.\n","PeriodicalId":72781,"journal":{"name":"Dental Oral Biology and Craniofacial Research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dental Oral Biology and Craniofacial Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/J.DOBCR.2021.03.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Introduction: Ameloblastoma is a benign odontogenic tumor that is aggressive and localised in nature,
listed as the first or second most prevalent odontogenic tumor and rarely tends to metastasis, but when it
does, it receives the definition adopted by the WHO in 2017 of metastasizing ameloblastoma.
Materials and Methods: This systematic review of clinical case reports of metastasizing ameloblastoma
from the last 10 years, collected from PubMed, ScienceDirect and Cochrane digital databases, aims to search
for association between clinical/pathological and/or molecular parameters of ameloblastoma and its
metastatic potential.
Results: The targeted search yielded 14 publications with a total of 18 clinical cases, which showed a mean
age for diagnosis of metastasizing ameloblastoma of 46 years, with no gender predilection and a high
probability of occurrence in the yellow Asian race, favouring a pattern of distant dissemination. The highest
frequency of metastasis was associated with mandibular primary lesions diagnosed in young patients, and
the most frequently found variant was the multicystic solid type, follicular subtype; distant metastasis was
the predominant form of presentation, with the lungs being the main target.
Conclusion: At the moment, there is nothing that can predict metastatic potential in ameloblastoma. More
standardised studies exploring the molecular terrain are needed, as this is a key and understudied factor.